These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 19473103)

  • 1. Histone acetyltransferase inhibitors and preclinical studies.
    Manzo F; Tambaro FP; Mai A; Altucci L
    Expert Opin Ther Pat; 2009 Jun; 19(6):761-74. PubMed ID: 19473103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological testing of novel pyridoisothiazolones as histone acetyltransferase inhibitors.
    Furdas SD; Shekfeh S; Bissinger EM; Wagner JM; Schlimme S; Valkov V; Hendzel M; Jung M; Sippl W
    Bioorg Med Chem; 2011 Jun; 19(12):3678-89. PubMed ID: 21353783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assays for the identification and evaluation of histone acetyltransferase inhibitors.
    Wynne Aherne G; Rowlands MG; Stimson L; Workman P
    Methods; 2002 Mar; 26(3):245-53. PubMed ID: 12054880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
    Mai A; Altucci L
    Int J Biochem Cell Biol; 2009 Jan; 41(1):199-213. PubMed ID: 18790076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties.
    Mai A; Rotili D; Tarantino D; Ornaghi P; Tosi F; Vicidomini C; Sbardella G; Nebbioso A; Miceli M; Altucci L; Filetici P
    J Med Chem; 2006 Nov; 49(23):6897-907. PubMed ID: 17154519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone acetyl transferases as emerging drug targets.
    Dekker FJ; Haisma HJ
    Drug Discov Today; 2009 Oct; 14(19-20):942-8. PubMed ID: 19577000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isoform-specific histone deacetylase inhibitors: the next step?
    Balasubramanian S; Verner E; Buggy JJ
    Cancer Lett; 2009 Aug; 280(2):211-21. PubMed ID: 19289255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.
    Epping MT; Bernards R
    Int J Biochem Cell Biol; 2009 Jan; 41(1):16-20. PubMed ID: 18765293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors.
    Prince HM; Bishton MJ; Johnstone RW
    Future Oncol; 2009 Jun; 5(5):601-12. PubMed ID: 19519200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved inhibition of the histone acetyltransferase PCAF by an anacardic acid derivative.
    Ghizzoni M; Boltjes A; Graaf Cd; Haisma HJ; Dekker FJ
    Bioorg Med Chem; 2010 Aug; 18(16):5826-34. PubMed ID: 20655754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curcumin is an inhibitor of p300 histone acetylatransferase.
    Marcu MG; Jung YJ; Lee S; Chung EJ; Lee MJ; Trepel J; Neckers L
    Med Chem; 2006 Mar; 2(2):169-74. PubMed ID: 16787365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of isothiazol-3-one derivatives as inhibitors of histone acetyltransferases (HATs).
    Gorsuch S; Bavetsias V; Rowlands MG; Aherne GW; Workman P; Jarman M; McDonald E
    Bioorg Med Chem; 2009 Jan; 17(2):467-74. PubMed ID: 19101154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells.
    Rahim R; Strobl JS
    Anticancer Drugs; 2009 Sep; 20(8):736-45. PubMed ID: 19584707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors: a new perspective for the treatment of leukemia.
    Abujamra AL; Dos Santos MP; Roesler R; Schwartsmann G; Brunetto AL
    Leuk Res; 2010 Jun; 34(6):687-95. PubMed ID: 19762081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and characterization of NK13650s, naturally occurring p300-selective histone acetyltransferase inhibitors.
    Tohyama S; Tomura A; Ikeda N; Hatano M; Odanaka J; Kubota Y; Umekita M; Igarashi M; Sawa R; Morino T
    J Org Chem; 2012 Oct; 77(20):9044-52. PubMed ID: 22984806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK inhibitors in cancer therapy: what is next?
    Malumbres M; Pevarello P; Barbacid M; Bischoff JR
    Trends Pharmacol Sci; 2008 Jan; 29(1):16-21. PubMed ID: 18054800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational combinations using HDAC inhibitors.
    Bots M; Johnstone RW
    Clin Cancer Res; 2009 Jun; 15(12):3970-7. PubMed ID: 19509171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dual-mode fluorescence strategy for screening HAT modulators.
    Xie N; Elangwe EN; Asher S; Zheng YG
    Bioconjug Chem; 2009 Feb; 20(2):360-6. PubMed ID: 19146394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone acetyltransferases: challenges in targeting bi-substrate enzymes.
    Wapenaar H; Dekker FJ
    Clin Epigenetics; 2016; 8():59. PubMed ID: 27231488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of p300 specific histone acetyltransferase inhibition by small molecules.
    Arif M; Pradhan SK; Thanuja GR; Vedamurthy BM; Agrawal S; Dasgupta D; Kundu TK
    J Med Chem; 2009 Jan; 52(2):267-77. PubMed ID: 19086895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.